360 NEWS360 NEWS

Business · National

Biocon gets European Commission nod for breast cancer biosimilar

First under new tailored clinical pathway; company’s fifth oncology biosimilar approved in Europe and the US

Verified Timeline

No verified timeline updates.

Voluntary Reader Opinion

What is your view on “Biocon gets European Commission nod for breast cancer biosimilar”?

This is self-selected reader participation, not representative scientific polling.